Appili Therapeutics
Tackling the Serious Global Challenges in Infectious Disease $APLI
Tackling the Serious Global Challenges in Infectious Disease $APLI
Appili Therapeutics is an infectious disease biopharmaceutical company founded in 2015 in Canada. The company's slogan "Tackling the Serious Global Challenges in Infectious Disease" underscores its commitment to addressing urgent infections with unmet needs. Appili Therapeutics is driven by its mission to develop a portfolio of novel therapies aimed at preventing deaths and improving lives. Through a $300.00K Post-IPO Debt investment received on 26 April 2024 from Bloom Burton & Co., Appili Therapeutics has demonstrated its ability to attract financial support from reputable investors. As a purpose-built, portfolio-driven, and people-focused company, Appili Therapeutics is strategically positioned to combat life-threatening infections and make a meaningful impact in the Biotechnology and Health Care industries. With its clear focus and recent financial backing, Appili Therapeutics has the potential to become a major player in the infectious disease treatment space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $400.00K | 1 |
|
26 Apr 2024 |
| Post-IPO Debt | $300.00K | 1 |
|
29 Jun 2023 |
| Post-IPO Debt | $2.50M | 1 | Long Zone Holdings | 20 Mar 2023 |
| Post-IPO Equity | $7.00M | - | 13 Oct 2021 | |
| Post-IPO Debt | $3.50M | 1 |
|
09 Aug 2021 |
No recent news or press coverage available for Appili Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
